Clinical trial NCT00392964: Patterns of Antiacids Use in Patients With IHD Admitted to Department of Internal Medicine
Official title: Patterns of Antiacids Use in Patients With IHD Admitted to Department of Internal Medicine
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ischemic Heart Disease
Keywords: Antacids
Proton pump inhibitors
aspirin
ischemic heart disease
Dyspepsia
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2006-10-26
Enrollment: 1200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: RETROSPECTIVE

Brief summary: There is substantial, continuing, and unexplained rise in prescribing of proton pump inhibitors. It is unknown whether their use in practice has corresponded to their licensed indications.

Although the indications for H2RA or PPI administration in the treatment of acid-related diseases and the prevention of gastric mucosal damage have been well defined in the medical literature, the perception of benefit from their use frequently tends to be extrapolated to all patients in general, leading to an excessive consumption of these drugs in general practice.

To date, however, little has been published with regard to the overall use or misuse of these drugs in hospital populations in ischemic heart disease patients as a secondary prevention to Aspirin use.

We will undertake a 6-months retrospective survey (about 1200 patients) to evaluate the use of acid-suppressive medications in the general internal medicine ward of Rambam Hospital.

We will extract all records of prescribing of a proton pump inhibitor within Rambam Hospital computerized patients file program (Premetheuos) in period of half year, categorized and analyze them using statistical X2 test.

Detailed description: Dyspeptic symptoms are a common presenting complaint, and there is continuing debate about management. Acid suppressant drugs, the most potent of which are proton pump inhibitors, are often prescribed, and it has been suggested that proton pump inhibitors are probably too widely prescribed for minor symptoms, and the cost implications of this are clear. There is substantial, continuing, and unexplained rise in prescribing of proton pump inhibitors. It is unknown whether their use in practice has corresponded to their licensed indications.

Although the indications for H2RA or proton pump inhibitor administration in the treatment of acid-related diseases and the prevention of gastric mucosal damage have been well defined in the medical literature, the perception of benefit from their use frequently tends to be extrapolated to all patients in general, leading to an excessive consumption of these drugs in general practice.

In addition, Physicians, nowadays tend to prescribe proton pump inhibitors for cardiac patients who use aspirin as secondary prevention of their illness.

To date, however, little has been published with regard to the overall use or misuse of these drugs in hospital populations, or to the fall-out of hospital prescriptions in general practice and none has been published regarding its use in ischemic heart disease patients as a secondary prevention to Aspirin use.

We will undertake a 6-months retrospective survey (about 1200 patients) to evaluate the use of acid-suppressive medications in the general internal medicine ward of Rambam Hospital, a large teaching hospital in Northern Israel; as well as the appropriateness of their prescription to the licensed indications, while dividing them to subgroups of ischemic heart disease patients.

We will extract all records of prescribing of a proton pump inhibitor within Rambam Hospital computerized patients file program (Premetheuos) in period of half year, categorized and analyze them using statistical X2 test.

Eligibility criteria: Inclusion Criteria:

* Ischemic Heart Disease

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam: Health Care Campus
city: Haifa
country: Israel
facility: Rambam Health Care Campus
Study officials:
affiliation: Acting Director of Internal Medicine "B"
name: Zaher S Azzam, MD
role: PRINCIPAL_INVESTIGATOR
References: